Clinical Trial Update: Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of umbralisib plus ublituximab in treatment-naïve follicular lymphoma was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-07-24